Performance of a guideline recommended algorithm for prognostication of neurological outcome after cardiac arrest

Marion Moseby-Knappe¹, MD, Erik Westhall², MD; PhD, Sofia Backman², MD, PhD, Niklas Mattsson-Carlsson³+⁴+⁵, MD, PhD, Irina Dragancea¹, MD, PhD, Anna Lybeck⁵, MD, PhD, Hans Friberg⁶, MD, PhD, Pascal Stammet⁷, MD, PhD, Gisela Lilja¹, OT, PhD, Janneke Horn⁸, MD, PhD, Jesper Kjaergaard⁹, MD, PhD, Christian Rylander¹⁰, MD, PhD, Christian Hassager⁹, MD, PhD, Susann Ullén¹¹, PhD, Niklas Nielsen¹², MD, PhD, and Tobias Cronberg¹, MD, PhD.

¹Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Neurology, Lund, Sweden
²Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Clinical Neurophysiology, Lund, Sweden
³Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden
⁴Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden
⁵Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Anaesthesia & Intensive Care, Lund, Sweden
⁶Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Anaesthesia & Intensive Care, Malmö, Sweden
⁷Medical and Health Department, National Fire and Rescue Corps, Luxembourg
⁸Department of Intensive Care, Amsterdam UMC, location Academic Medical Center, Amsterdam, Netherlands
⁹Department of Cardiology, Rigshospitalet and Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
¹⁰Department of Anaesthesiology and Intensive Care Medicine, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
¹¹Clinical Studies Sweden - Forum South, Skane University Hospital, Lund, Sweden.
¹²Lund University, Helsingborg Hospital, Department of Clinical Sciences Lund, Anaesthesia & Intensive Care, Lund, Sweden
Table of Contents

eFigure 1 Flow-chart of patient inclusion

eFigure 2 Overview over additional pathological prognostic findings in patients with bilaterally absent N20 potentials on SSEP in Step 2

eFigure 3 Flowchart ERC/ESICM algorithm with alternative definitions of outcome (CPC 1-3 versus CPC 4-5).

eFigure 4 Number of pathological findings in relation to Glasgow Coma Scale Motor Score on day 4

eTables 1A+B McNemar’s Test for comparison of prognostic accuracies of single methods in combined models predicting poor outcome

eTable 2 WLST due to neurological futility for TP patients for each prognostic method

eTable 3 Baseline data for TN and FN patients with GCS-M≥3 in Step 1 of the ERC/ESICM algorithm

eTable 4 Good outcome patients (CPC 1-2) with GCS-M≤2 on day 4 (n=14)

eTable 5 Good outcome patients (CPC 1-2) with single pathological findings (n=9)

eTables 6A+B GCS-M and pathological neuroprognostic findings

eTable 7 Sensitivities and specificities of single prognostic methods recalculated excluding patients with WLST due to neurological futility
eFigure 1 Flow-chart of patient inclusion

Numbers of patients assessed for eligibility, excluded and included patients. The blue boxes to the left indicate the two different cohorts used for statistical analyses. Missing outcome refers to patients where 6-month Cerebral Performance Category Scale was unavailable. GCS-M; Glasgow Coma Scale Motor Score on day 4 post-arrest.
Number (percentages) of additional pathological prognostic findings in patients fulfilling the Step 2 criterion of bilaterally absent N20 potentials on SSEP. For example, only 7/53 (13.2%) of patients with bilaterally absent N20 had no other pathological Step 2 or Step 3 criteria. 32.1% of patients with bilaterally absent N20 had 1 other finding, mostly elevated serum Neuron-specific enolase (NSE). NSE serum concentrations are presented as median (interquartile range) in those patients with NSE elevated ≥48 pg/mL at 48 hours or ≥38 pg/mL at 72 hours post-arrest. PRCR: bilaterally absent pupillary and bilaterally absent corneal reflexes; pathological EEG according to ERC/ESICM criteria, early status myoclonus <48 hours post-arrest; pathological CT or MRI: generalized oedema according to local radiologists; WLST-N: withdrawal of life-sustaining therapy due to presumed neurological futility. Please note that serum NSE concentrations were analyzed after trial completion and result were not available when deciding on WLST.
Flowchart using an alternative definition of good (CPC 1-3) versus poor (CPC 4-5) neurological outcome at 6 months post-arrest. In this analysis, 1 patient with CPC 3 fulfilled criteria for “poor outcome likely” in Step 3 and was classified as false positive (FP). Pathological findings of the CPC 3 patient were generalized oedema on CT 159 hours post-arrest, pathological EEG after 54 h according to ERC/ESICM criteria and elevated NSE at 48 and 72 hours (68.4 and 66.6 pg/mL, respectively). This patient was classified as modified Rankin Scale 4 at 6 months. The definitions of pathological prognostic examinations used to predict poor outcome are identical to those used in Figure 1.
eFigure 4 Number of pathological findings in relation to Glasgow Coma Scale Motor Score on day 4

The stacked bar chart displays Glasgow Coma Scale Motor Score (GCS-M) level on day 4 post-arrest, numbers (number on bar chart) and percentages (on the y-axis) of corresponding pathological neuroprognostic findings according to the ERC/ESICM algorithm (Step 2 and/or Step 3). The findings of this bar chart is the sum of eTable 5A (good outcome patients) and eTable 5B (poor outcome patients).
Table 1 McNemar’s Test for comparison of prognostic accuracies of single methods in combined models predicting poor outcome

A. Comparing single sensitivities within combined models

| Sensitivities compared | Poor outcome and examined n= | Pathological test A n= | Pathological test B n= | Pathological test A+ B n= | Both tests normal n= | P-value |
|------------------------|-----------------------------|-----------------------|-----------------------|--------------------------|---------------------|---------|
| SSEP / PRCR            | 137                         | SSEP = 34             | PRCR = 4              | SSEP & PRCR = 23         | 76                  | <0.001*** |
| SSEP / NSE             | 129                         | SSEP = 4              | NSE = 39              | SSEP & NSE = 53          | 33                  | <0.001*** |
| SSEP / EEG             | 134                         | SSEP = 44             | EEG = 34              | SSEP & EEG = 14          | 42                  | 0.31    |
| SSEP / CT              | 91                          | SSEP = 25             | CT = 15               | SSEP & CT = 14           | 37                  | 0.15    |
| SSEP / S. myoclonus    | 161                         | SSEP = 59             | S. M. = 3             | SSEP & S. M. = 14        | 85                  | <0.001***|
| SSEP / MRI             | 19                          | SSEP = 1              | MRI = 2               | SSEP & MRI = 1           | 15                  | 1       |
| PRCR / NSE             | 188                         | PRCR = 4              | NSE = 102             | PRCR & NSE = 31          | 51                  | <0.001***|
| PRCR / EEG             | 171                         | PRCR = 24             | EEG = 51              | PRCR & EEG = 8           | 88                  | 0.003** |
| PRCR / CT              | 150                         | PRCR = 19             | CT = 40               | PRCR & CT = 15           | 76                  | 0.009** |
| PRCR / S. myoclonus    | 254                         | PRCR = 46             | S. M. = 14            | PRCR & S. M. = 5         | 189                 | <0.001***|
| PRCR / MRI             | 20                          | PRCR = 0              | MRI = 2               | PRCR & MRI = 1           | 17                  | 0.48    |
| NSE / EEG              | 176                         | NSE = 79              | EEG = 14              | NSE & EEG = 41           | 42                  | <0.001***|
| NSE / CT               | 163                         | NSE = 57              | CT = 7                | NSE & CT = 47            | 52                  | <0.001***|
| NSE / S. myoclonus     | 309                         | NSE = 170             | S. M. = 3             | NSE & S. M. = 16         | 120                 | <0.001***|
| NSE / MRI              | 18                          | NSE = 6               | MRI = 0               | NSE & MRI = 3            | 9                   | 0.04*   |
| EEG / CT               | 133                         | EEG = 27              | CT = 27               | EEG & CT = 16            | 63                  | 1       |
| EEG / S. myoclonus     | 221                         | EEG = 63              | S. M. = 10            | EEG & S. M. = 7          | 141                 | <0.001***|
| EEG / MRI              | 16                          | EEG = 7               | MRI = 3               | EEG & MRI = 0            | 6                   | 0.34    |
| CT / S. myoclonus      | 235                         | CT = 71               | S. M. = 11            | CT & S. M. = 5           | 148                 | <0.001***|
| CT / MRI               | 13                          | CT = 1               | MRI = 2               | CT & MRI = 1             | 9                   | 1       |
| S. myoclonus / MRI     | 23                          | S. M. = 1             | MRI = 3               | S. M. & MRI = 0          | 19                  | 0.62    |

This is a contingency table comparing sensitivities for prediction of poor outcome by combinations of tests using the McNemars’s Test for dependent variables. Significance levels are also indicated in Table 3 by asterisks (*). Only poor outcome patients (CPC 3-5) examined with both methods of a given combination were included in the estimation of sensitivity, therefore sensitivities of single methods within combinations may differ from those reported for each method separately (Tables 2 and 3). The columns describe which pair of methods is examined and total number of poor outcome patients examined with this combination (n), number of patients with pathological findings of method A, B and A+B respectively, and the number of poor outcome patients without pathological findings. *p<0.05, **p<0.01, ***p<0.001. A significant difference indicate that one method contributes more to the overall sensitivity of the combined model A/B. PRCR; bilaterally absent pupillary and bilaterally absent corneal reflexes, CT; head computed tomography, MRI; magnetic resonance imaging, NSE; serum neuron specific enolase, EEG; electroencephalogram, S. myoclonus; status myoclonus. The definitions of pathological findings according to ERC/ESICM used in this study is described in the methods section.
### B. Comparing single specificities within combined models

| Specificities compared | Good outcome and examined n= | Pathological test A n= | Pathological test B n= | Pathological test A+ B n= | Both tests normal n= | P-value |
|------------------------|-----------------------------|-----------------------|-----------------------|--------------------------|---------------------|---------|
| SSEP / PRCR            | 27                          | SSEP = 1              | PRCR = 0              | SSEP & PRCR = 0          | 26                  | NA      |
| SSEP / NSE             | 32                          | SSEP = 1              | NSE = 2               | SSEP & NSE = 0           | 29                  | 1       |
| SSEP / EEG             | 29                          | SSEP = 1              | EEG = 0               | SSEP & EEG = 0           | 28                  | NA      |
| SSEP / CT              | 7                           | SSEP = 0              | CT = 0                | SSEP & CT = 0            | 7                   | NA      |
| SSEP / S. myoclonus    | 39                          | SSEP = 1              | S.M. = 0              | SSEP & S.M. = 0          | 38                  | NA      |
| SSEP / MRI             | 3                           | SSEP = 0              | MRI = 0               | SSEP & MRI = 0           | 3                   | NA      |
| PRCR / NSE            | 36                          | PRCR = 0              | NSE = 2               | PRCR & NSE = 0          | 34                  | NA      |
| PRCR / EEG             | 31                          | PRCR = 0              | EEG = 0               | PRCR & EEG = 0          | 31                  | NA      |
| PRCR / CT             | 15                          | PRCR = 0              | CT = 0                | PRCR & CT = 0           | 15                  | NA      |
| PRCR / S. myoclonus   | 47                          | PRCR = 0              | S.M. = 1              | PRCR & S.M. = 0         | 46                  | NA      |
| PRCR / MRI            | 4                           | PRCR = 0              | MRI = 0               | PRCR & MRI = 0          | 4                   | NA      |
| NSE / EEG             | 65                          | NSE = 4              | EEG = 1               | NSE & EEG = 0           | 60                  | 0.37    |
| NSE / CT              | 91                          | NSE = 3              | CT = 2                | NSE & CT = 0           | 86                  | 1       |
| NSE / S. myoclonus    | 337                         | NSE = 12             | S.M. = 0              | NSE & S.M. = 0         | 325                 | NA      |
| NSE / MRI             | 6                           | NSE = 1              | MRI = 0               | NSE & MRI = 0          | 5                   | NA      |
| EEG / CT              | 31                          | EEG = 1              | CT = 0                | EEG & CT = 0           | 31                  | NA      |
| EEG / S. myoclonus    | 84                          | EEG = 1              | S.M. = 1              | EEG & S.M. = 0        | 82                  | 1       |
| EEG / MRI             | 9                           | EEG = 0              | MRI = 0               | EEG & MRI = 0          | 9                   | NA      |
| CT / S. myoclonus     | 121                         | CT = 2              | S.M. = 0              | CT & S.M. = 0        | 119                 | NA      |
| CT / MRI              | 5                           | CT = 0              | MRI = 0               | CT & MRI = 0          | 5                   | NA      |
| S. myoclonus / MRI    | 12                          | S.M. = 0              | MRI = 0               | S.M. & MRI = 0        | 12                  | NA      |

This is a contingency table comparing specificities for prediction of poor outcome by combinations of tests using the McNemars’s Test for dependent variables. Only good outcome patients (CPC 1-2) examined with both methods of a given combination were included in the estimation of specificity, therefore specificities of single methods within combinations may differ from those reported for each method separately (Tables 2 and 3). The columns describe which pair of methods is examined and total number of good outcome patients examined with this combination (n), number of patients with pathological findings of method A, B and A+B respectively, and the number of good outcome patients without pathological findings. p<0.05 was considered statistically significant. NA indicates that no p-value could be calculated because at least one of the prognostic methods had 0 pathological findings. PRCR; bilaterally absent pupillary and bilaterally absent corneal reflexes, CT; head computed tomography, MRI; magnetic resonance imaging, NSE; serum neuron specific enolase, EEG; electroencephalogram, S. myoclonus; status myoclonus. The definitions of pathological findings according to ERC/ESICM used in this study is described in the methods section.
### eTable 2 Number of WLST due to neurological futility for TP patients for each prognostic method

| Pathological findings          | n=  | Poor outcome (%) | WLST-N in poor outcome patients (%) |
|-------------------------------|-----|------------------|-------------------------------------|
| Glasgow Coma Scale-Motor ≤2  | 205 | 191 (93.2)       | 113/191 (59.2)                      |
| PR/CR                         | 51  | 51 (100.0)       | 38/51 (74.5)                        |
| SSEP                          | 74  | 73 (98.6)        | 64/73 (87.7)                        |
| Status myoclonus              | 35  | 34 (97.1)        | 23/34 (67.6)                        |
| Elevated NSE                 | 198 | 186 (93.9)       | 116/186 (62.4)                      |
| EEG                           | 71  | 70 (98.6)        | 55/70 (78.6)                        |
| CT                            | 78  | 76 (97.4)        | 54/76 (71.1)                        |
| MRI                           | 3   | 3 (100.0)        | 2 (66.7)                            |

This table describes number of patients with pathological findings for each prognostic examination in Steps 1-3 of the ERC/ESICM algorithm, number and percentage of poor outcome patients (CPC 3-5 at 6 months post-arrest), and number and percentage of patients with withdrawal of life-sustaining therapy due to presumed neurological futility (WLST-N). PR/CR; bilaterally absent pupillary and bilaterally absent corneal reflexes. Please see methods section for definitions of pathological findings used in this study.
**eTable 3 Baseline data for good and poor outcome patients with GCS-M≥3 in Step 1 of the ERC/ESICM algorithm**

| Findings                  | TN Step 1 (n=305) | FN Step 1 (n=75) | p-value |
|---------------------------|-------------------|------------------|---------|
| Age (years)               | 62 (52-60)        | 71 (64-71)       | <0.001 |
| Sex male                  | 256 (83.9)        | 58 (77.3)        | 0.24   |
| Time to ROSC (min.)       | 20 (13-24)        | 23 (15-29)       | 0.036  |
| Initial rhythm shockable  | 286 (93.8)        | 58 (77.3)        | <0.001 |

Baseline data of patients with Glasgow Coma Scale Motor Score (GCS-M) ≥3 on day 4 in Step 1 of the ERC/ESICM algorithm. Good outcome patients (CPC 1-2 at 6 months post-arrest) were classified as true negative (TN) and poor outcome patients (CPC 3-5) were classified as false negative (FN). Continuous variables are presented as median (interquartile range) and p-values were calculated with the Mann-Whitney-Test. Binary variables are presented in numbers (percentages) and p-values were calculated using Chi-Square-Test.
### eTable 4 Good outcome patients (CPC 1-2) with GCS-M≤2 on day 4 (n=14)

| #  | Day 4 GCS-M | Age (years) /sex | Minutes to ROSC | Initial rhythm | Time to awakening | NSE 24 (pg/mL) | NSE 48 (pg/mL) | NSE 72 (pg/mL) | CPC ICU discharge | Hours from CA to ICU discharge | CPC at 6 months | Length of hospital stay (h) |
|----|-------------|------------------|-----------------|----------------|------------------|----------------|----------------|----------------|-----------------|-------------------------------|----------------|--------------------------|
| 1  | 1           | 57, male         | 16              | VF             | Day 7: GCS-M 1   | NA             | NA             | NA             | 4               | 149                           | 2              | 1682                     |
| 2  | 1           | 80, male         | 25              | VF             | Day 6: obeys commands | 14.5           | 15.1           | 6.9            | 1               | 282                           | 1              | 556                      |
| 3  | 1           | 62, male         | 51              | VF             | Day 7: GCS-M 4   | 22.0           | 19.5           | 15.7           | 3               | 690                           | 1              | 975                      |
| 4  | 1           | 74, male         | 45              | VF             | Day 5: obeys commands | NA             | NA             | NA             | 2               | 117                           | 1              | 269                      |
| 5  | 1           | 61, male         | 20              | VF             | Day 6: obeys commands | 7.3            | 5.7            | 3.4            | 1               | 911                           | 1              | 1199                     |
| 6  | 1           | 43, male         | 25              | VF             | Day 7: GCS-M 4   | 24.9           | 10.8           | 7.6            | 2               | 311                           | 1              | 411                      |
| 7  | 1           | 80, male         | 13              | VF             | Day 7: GCS-M 4   | 34.3           | 26.2           | 15.7           | 3               | 850                           | 2              | 1826                     |
| 8  | 1           | 63, male         | 23              | Asystole       | Day 7: obeys commands | 6.8            | 8.8            | 6.4            | 3               | 313                           | 1              | 1595                     |
| 9  | 1           | 56, male         | 12              | VF             | Day 5: obeys commands | 13.2           | 18.1           | 6.4            | 2               | 140                           | 1              | 389                      |
| 10 | 1           | 61, male         | 35              | VF             | Day 7: obeys commands | NA             | NA             | NA             | 2               | 454                           | 1              | 882                      |
| 11 | 1           | 39, male         | 30              | VF             | Day 6: obeys commands | 37.9           | 27.6           | 16.2           | 1               | 158                           | 1              | 206                      |
| 12 | 2           | 57, male         | 37              | VF             | Missing data     | NA             | NA             | NA             | 4               | 89                            | 2              | Unknown                  |
| 13 | 1           | 73, male         | 25              | VF             | Day 6: obeys commands | 43.3           | 48.2           | 46.3           | 2               | 124                           | 2              | 340                      |
| 14 | 2           | 75, male         | 22              | VF             | Day 3 and day 7: GCS-M 5 | 11.8           | 12.6           | 8.1            | 3               | 175                           | 2              | 242                      |

This table informs about the fourteen patients with Glasgow Coma Scale Motor (GCS-M) 1 (no reaction) or 2 (extension posture) on day 4 post-arrest. All patients were male, 13/14 had ventricular fibrillation (VF) on ECG. Time to awakening describes the first day when patient is awake and obeys commands (GCS-M 6) or best GCS-M on day 7 post-arrest. ROSC, return of spontaneous circulation; VF, ventricular fibrillation; NSE, serum neuron specific enolase; mRS, modified Rankin Scale 6 months post-arrest; CPC, Cerebral Performance Category Scale 6 months post-arrest; CA, cardiac arrest.
| #  | Pathological examination | Age (years) /sex | Minutes to ROSC | Initial rhythm | Bystander CPR | Day 4 GCS-M | NSE 24 (pg/mL) | NSE 48 (pg/mL) | NSE 72 (pg/mL) | Comment: | mRS at 6 months | CPC at 6 months | Length of hospital stay (h) |
|----|--------------------------|------------------|-----------------|----------------|--------------|-------------|---------------|---------------|---------------|----------|----------------|----------------|-------------------------|
| 1  | NSE 48                   | 46, male         | 35              | PEA            | YES          | 6 (obeys commands) | 11.54         | 49.54         | 35.85         | Awake on day 4 | 0               | 1               | 413                     |
| 2  | NSE 48                   | 67, male         | 20              | VF             | NO           | 4 (withdrawal to painful stimulus) | 52.54         | 49.16         | 22.42         | EEG: benign Haemolysis? Decreasing NSE from 24 to 72h | 0               | 1               | 1823                    |
| 3  | NSE 48                   | 64, female       | 22              | VF             | NO           | 6 (obeys commands) | 75.64         | 67.34         | 34.43         | Haemolysis? Decreasing NSE from 24 to 72h. Awake on day 4 | 1               | 1               | 306                     |
| 4  | NSE 48/72                | 73, male         | 25              | VF             | YES          | 1 (no reaction)  | 43.25         | 48.21         | 46.34         | CT 99 h, normal | 0               | 1               | 340                     |
| 5  | NSE 48/72                | 73, male         | 11              | VF             | YES          | 6 (obeys commands) | 106.3         | 74.92         | 47.97         | Haemolysis? Decreasing NSE from 24 to 72h. Awake on day 4 | 2               | 1               | 461                     |
| 6  | NSE 72                   | 65, male         | 7               | VF             | YES          | 6 (obeys commands) | 7.84          | 13.06         | 40.47         | Awake on day 4 | 0               | 1               | 256                     |
| 7  | NSE 72                   | 80, male         | 40              | Non-perfusing VT | YES         | 6 (obeys commands) | 36.8          | 26.26         | 43.98         | SSEP N20 bilat present. Awake on day 4 | 0               | 1               | 716                     |
| 8  | EEG: unreactive status epilepticus | 65, male   | 15              | VF             | YES          | 5 (localizes to painful stimulus) | 11.32         | NA            | 9.97          | EEG: generalized abundant periodic discharges >50%, continuous normal voltage background. Unreactive according to local investigators. CT 153 h: normal | 1               | 1               | 368                     |
| 9  | Early status myoclonus ≤48h | 63, male      | 12              | VF             | NO           | 6 (obeys commands) | NA            | NA            | NA            | Awake on day 4 | 1               | 2               | 642                     |

The table describes the nine good outcome patients with single pathological findings identified in Step 3 of the ERC/ESICM algorithm. ROSC, return of spontaneous circulation; PEA, pulseless electric activity; VF, ventricular fibrillation; CPR, cardiopulmonary resuscitation; Day 4 GCS-M, Glasgow Coma Scale Motor Score on day 4 post-arrest; NSE, serum neuron specific enolase; mRS, modified Rankin Scale 6 months post-arrest; CPC, Cerebral Performance Category Scale 6 months post-arrest. Six of
these nine patients with single false pathological findings were awake on day 4 post arrest and obeying commands (GCS-M 6) (patients #1, #3, #5, #6, #7, and #9). Three of seven patients with elevated NSE had decreasing levels of NSE from 24 h to 72 h post-arrest (patients #2, #3 and #5).
eTables 6 A+B GCS-M and pathological neuroprognostic findings

A. Good outcome (CPC 1-2 at 6 months post-arrest)

| Sum path. findings | GCS-M day 4 |
|--------------------|-------------|
|                    | 1 (n=12)   | 2 (n=2) | 3 (n=9) | 4 (n=29) | 5 (n=46) | 6 (n=221) | All CPC 1-2 (n=319) |
| 0                  | 11 (3.8)   | 2 (0.6) | 9 (2.8) | 28 (9.1) | 45 (14.4)| 215 (69.3) | 310                  |
| 1                  | 1 (0.6)    | 0 (0)   | 0 (0)   | 1 (1)    | 1 (1)   | 6 (2)     | 9                    |
| ≥2                 | 0 (0)      | 0 (0)   | 0 (0)   | 0 (0)    | 0 (0)   | 0 (0)     | 0                    |

B. Poor outcome (CPC 3-5 at 6 months post-arrest)

| Sum path. findings | GCS-M day 4 |
|--------------------|-------------|
|                    | 1 (n=160)  | 2 (n=31) | 3 (n=14) | 4 (n=23) | 5 (n=16) | 6 (n=22) | All CPC 3-5 (n=266) |
| 0                  | 33 (60.2)  | 5 (11.7) | 5 (5.3)  | 13 (8.6) | 15 (6.0) | 21 (8.2) | 92                   |
| 1                  | 52 (11.7)  | 9 (0)    | 3 (0)    | 6 (0)    | 1 (0)    | 1 (0)    | 72                   |
| 2                  | 48 (8.6)   | 7 (0)    | 4 (0)    | 3 (0)    | 0 (0)    | 0 (0)    | 62                   |
| 3                  | 21 (3.8)   | 6 (0)    | 1 (0)    | 1 (0)    | 0 (0)    | 0 (0)    | 29                   |
| 4                  | 6 (1)      | 4 (0)    | 1 (0)    | 0 (0)    | 0 (0)    | 0 (0)    | 11                   |

The tables describe numbers (%) of Glasgow Coma Scale Motor Score (GCS-M) on day 4 post-arrest and the sum of pathological neuroprognostic findings according to ERC/ESICM (step 2/3). The total sum of findings in eTable 6A (good outcome) and eTable 6B (poor outcome) are displayed in the stacked bar chart in eFigure 3. Pathological findings were defined as: bilaterally absent pupillary and corneal reflexes, bilaterally absent N20-potentials on SSEP, early status myoclonus ≤48 hours, generalized edema on CT or MRI, elevated Neuron specific enolase (NSE) ≥48 pg/mL at 48 hours and/or ≥38 pg/mL at 72 hours or pathological EEG according to ERC/ESICM criteria.
Recalculation of sensitivities and specificities of prognostic methods as demonstrated in Table 2 excluding all patients with withdrawal of life-sustaining therapy (WLST) due to presumed neurological futility (n=211). Results presented with 95% confidence intervals together with the number of correctly and incorrectly diagnosed patients with poor neurological outcome defined as Cerebral Performance Category Scale 3-5 at 6 months. Only patients with available results to be classified as pathological in the examined methods were included in the statistical analyses. All definitions of pathological findings are identical to those in Table 2 and are describes in the methods section of the article. TP, true positive (predicted and reported outcome CPC 3-5); TN, true negative (predicted and reported outcome CPC 1-2); FP, false positive (predicted CPC 3-5, reported outcome CPC 1-2), FN, false negative (predicted CPC 1-2, reported outcome CPC 3-5).

| Method                      | Sensitivity (95% CI) | Specificity (95% CI) | TP  | TN  | FP  | FN  | N=  | Poor outcome |
|-----------------------------|----------------------|----------------------|-----|-----|-----|-----|-----|--------------|
| GCS-M ≤2                    | 56.5 (48.2-64.5)     | 95.6 (92.8-97.4)     | 78  | 305 | 14  | 60  | 457 | 138 (30.2)  |
| GCS-M ≤3                    | 60.1 (51.8-67.9)     | 92.8 (89.4-95.2)     | 83  | 296 | 23  | 55  | 457 | 138 (30.2)  |
| GCS-M ≤4                    | 72.5 (64.5-79.2)     | 83.7 (79.3-87.4)     | 100 | 267 | 52  | 38  | 457 | 138 (30.2)  |
| PR/CR                       | 14.8 (8.8-23.7)      | 100.0 (92.4-100.0)   | 13  | 47  | 0   | 75  | 135 | 88 (65.2)   |
| SSEP                        | 18.8 (10.2-31.9)     | 97.4 (86.8-99.6)     | 9   | 38  | 1   | 39  | 87  | 48 (55.2)   |
| NSE ≥ 33/*/*                | 51.2 (43.6-58.8)     | 89.9 (86.2-92.7)     | 84  | 303 | 34  | 80  | 501 | 164 (32.7)  |
| NSE ≥48/*≥38/**             | 42.7 (35.4-50.3)     | 96.4 (93.9-98.0)     | 70  | 325 | 12  | 94  | 501 | 164 (32.7)  |
| EEG ERC/ESICM               | 17.4 (10.9-26.8)     | 98.8 (93.6-99.8)     | 15  | 83  | 1   | 71  | 170 | 86 (50.6)   |
| EEG “highly malignant”      | 27.9 (19.5-38.2)     | 98.8 (93.6-99.8)     | 24  | 83  | 1   | 62  | 170 | 86 (50.6)   |
| Status Myoclonus ≤ 48h      | 3.9 (2.2-6.9)        | 99.8 (98.7-100.0)    | 11  | 439 | 1   | 271 | 722 | 282 (39.1)  |
| CT                          | 21.1 (14.4-30.0)     | 98.3 (94.2-99.6)     | 22  | 119 | 2   | 82  | 225 | 104 (46.2)  |
| MRI                         | 9.1 (1.6-37.7)       | 100.0 (75.8-100.0)   | 1   | 12  | 0   | 10  | 23  | 11 (47.8)   |
|                            |                      |                      |     |     |     |     |     |              |

eTable 7 Sensitivities and specificities of single prognostic methods recalculated excluding patients with WLST due to neurological futility.